Navigation Links
New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
Date:11/9/2010

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- The addition of Cimzia® (certolizumab pegol; CZP) to current therapy was associated with a rapid clinical response, improved function and reduced disease activity in a diverse group of adult rheumatoid arthritis (RA) patients reflecting those seen in daily clinical practice (including those with prior TNF-inhibitor use).  These positive clinical trial data were presented during the American College of Rheumatology's (ACR) 2010 Annual Scientific Meeting in Atlanta, November 7-11. Cimzia®  is approved for the treatment of adults with moderately to severely active rheumatoid arthritis.

"There are patients who live with little relief from the painful symptoms of rheumatoid arthritis due to failed therapies or the severity of the condition," said Roy Fleischmann, MD, clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical School.  "These data emphasize that treatment with Cimzia® can substantially provide rapid improvements and help reduce disease activity regardless of the patient's disease history in many of these patients."

The data presented were from the REALISTIC (RA Evaluation in Subjects Receiving TNF Inhibitor Certolizumab Pegol) multicenter phase IIIb study, which included a 12-week, randomized, double-blind (DB), placebo-controlled phase followed by an open-label extension (OLE) (greater than or equal to 16 weeks).  REALISTIC was designed to investigate the safety and efficacy of CZP in a broad patient population with active RA more closely resembling routine clinical practice, versus the pivotal trials, including patients with/without prior TNF-inhibitor exposure, with/without concomitant methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs); and varying lengths of disease duration.

The primary endpoint of an ACR20 score at week 12 was met.  At week 12, more than half (51.1%) of patients in the
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
2. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
3. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
4. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
5. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
6. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
7. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. Marken Rapidly Responds to Global Supply Chain Security Measures
10. Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
11. Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... MONTREAL , Nov. 21, 2014 /PRNewswire/ ... that the European Medicines Agency (EMA) has ... the company,s lead product candidate, for the ... is a rare, severely disabling genetic disease ... tissue swelling (flare-ups) and new abnormal bone ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Chief Executive Officer, will be presenting at the 26 th ... Palace Hotel in New York . The ... 2:00 PM ET. In addition, Mr. Krakauer and Jorgen ... separate one-on-one meetings during the day. An ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3
... be Presented, PRINCETON, N.J., Sept. 4 ... nine clinical abstracts for ipilimumab,an investigational anti-CTLA-4 antibody, ... presentations at the 33rd Congress of the European ... 2008 in Stockholm.,Many of the following abstracts will ...
... for Targeted Therapies ... Benefits of Personalized Treatment HUNTINGTON BEACH, ... leader in molecular cancer diagnostics,today announced the launch of ... determine the gene expression levels of,the estrogen receptor (ER), ...
Cached Medicine Technology:Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Agendia Launches TargetPrint(R) for Breast Cancer Patients 2
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand in wedding dresses, ... business offers a wide range of special occasion dresses, ... them to create multiple looks easily. , According to ... of chic wedding dresses has been prepared for many ... rates now. Dylan Queen can always create what ladies ...
(Date:11/22/2014)... November 22, 2014 Nocturia is ... the complaint that the individual has to wake ... The report “Nocturia – Pipeline Review, H2 2014” ... Nocturia, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:11/22/2014)... The topic of B&D Rockeries’ latest publication is ... states that, “While they give off the appearance of simplicity ... creating this powerful look.” , One of the first and ... kind of block matches your home environment and best fulfills ... main options are concrete and stone blocks. But do not ...
(Date:11/22/2014)... St. Petersburg, FL (PRWEB) November 22, 2014 ... Kitchen Innovations are pleased to announce that ... of the Thanksgiving #PayItForward contest. , Ms. Lombardo ... package from Kitchen Innovations. She wrote of how her ... beautiful, young daughters as a single mom. Despite medical ...
(Date:11/22/2014)... November 22, 2014 “Greenfield Naturals” was ... Tech Report , which features the latest and coolest ... expert and reporter for NewsWatch, conducted the product review ... the flavor of your water. , From pollution to ... important that everything is done to remove these chemicals, ...
Breaking Medicine News(10 mins):Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2
... Jerrold ... Connolly Medical Ltd. , ... (Vocus) January 29, 2010 -- Berkeley Heights – Jerrold S. Lozner, M.D., M.H.A., ... named as a “Top Doctor for Women’s Health” by Castle Connolly Medical, Ltd, in ...
... Pa. , Jan. 29 The Susan P. ... educate and inspire people of all ages to make healthy ... as President and CEO.  A talented non-profit leader, his goal ... expanding the delivery and distribution of health education services by ...
... , , Provides oral regime for hormone ... SPRING, Md. , Jan. 29 The U.S. ... with Femara (letrozole) to treat hormone positive and HER2-positive advanced ... indicated. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , HER2 ...
... respiratory weakness as a factor in the morbidity of ... that could improve long-term patient outcomes while reducing costs ... chair of research for the Department of Internal Medicine ... awarded a highly competitive, two-year, $480,000/year NIH Challenge Grant ...
... ... Following is the National Council on Disability,s monthly bulletin for December ... NCD,s award-winning Web site ( http://www.ncd.gov ), brings you the latest issues ... go to http://listserv.access.gpo.gov , click on "Online mailing list archives," select ...
... HANOVER TOWNSHIP, Pa. , Jan. 29 During a ... Secretary Everette James and Secretary of Education Gerald ... activity among middle school students. , "One-third of all Pennsylvania ... a lifetime of health problems," said James. "Schools like Hanover ...
Cached Medicine News:Health News:Summit Medical Group Physician Named 'Top Doctor for Women's Health' 2Health News:Susan P. Byrnes Health Education Center Names C.T. O'Donnell President and CEO 2Health News:Susan P. Byrnes Health Education Center Names C.T. O'Donnell President and CEO 3Health News:FDA Expands Use of Approved Breast Cancer Drug 2Health News:FDA Expands Use of Approved Breast Cancer Drug 3Health News:Kentucky research looks at respiratory weakness in ICU morbidity 2Health News:National Council on Disability Monthly Bulletin for January 2010 2Health News:National Council on Disability Monthly Bulletin for January 2010 3Health News:National Council on Disability Monthly Bulletin for January 2010 4Health News:National Council on Disability Monthly Bulletin for January 2010 5Health News:National Council on Disability Monthly Bulletin for January 2010 6Health News:National Council on Disability Monthly Bulletin for January 2010 7Health News:National Council on Disability Monthly Bulletin for January 2010 8Health News:National Council on Disability Monthly Bulletin for January 2010 9Health News:State Health, Education Leaders Applaud Luzerne County School for Boosting Physical Activity Among Students 2
... your camera upon arrival.,Our technician then makes note ... with a thorough customer quote. We respect that ... so well help you prioritize repairs. With customer ... , ISI uses only OEM or widely approved ...
... carefully inspects your equipment upon arrival. Our technician ... and provides you with a thorough customer quote. ... a tight budget so well help you prioritize ... repair begins., , ISI uses only OEM or ...
... Infinity™ AST single liquid stable reagent ... quantitative determination of AST in serum. ... only provides excellent stability and convenience ... against existing assays. The reagent is ...
... Konelab 30 is a fully automated, versatile ... analytical needs in mind. Konelab 30 is ... tests, specific proteins, therapeutic drugs, drugs of ... applications. Its flexibility also makes the analyzer ...
Medicine Products: